Dr. Mehran Taban, M.D.
Ophthalmology (Ophthalmology Physician)
20528 Hawthorne Blvd Ste 201
Torrance, CA 90503
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Irvine, California College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,387
Licensed in California since 2009, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of California, Irvine, California College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A108546 (first issued 2009; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Mehran Taban MD Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,387
- Services billed
- 37,472
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 6,720 | 28 |
| Imaging of retina | 5,232 | 1,304 |
| Injection of drug into eye | 4,546 | 536 |
| Compounded drug, not otherwise classified | 4,028 | 511 |
| Injection of drug into cavity behind eye | 3,774 | 479 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 2,640 | 39 |
| 2d ultrasound scan of eye tissue and structures | 2,606 | 979 |
| Established patient complete exam of visual system | 2,223 | 1,156 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 1,641 | 643 |
| Established patient problem focused exam of visual system | 1,585 | 532 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ciprofloxacin Hcl Other prescribers in Torrance, CA | 1,413 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Torrance, CA | 502 |
| Latanoprost Other prescribers in Torrance, CA | 343 |
| Brimonidine Tartrate Other prescribers in Torrance, CA | 290 |
| Timolol Maleate Other prescribers in Torrance, CA | 253 |
| Prednisolone Acetate Other prescribers in Torrance, CA | 186 |
| Tobramycin-Dexamethasone (tobramycin/dexamethasone) Other prescribers in Torrance, CA | 99 |
| Lumigan (bimatoprost) Other prescribers in Torrance, CA | 91 |
| Ofloxacin Other prescribers in Torrance, CA | 48 |
| Simbrinza (brinzolamide/brimonidine tart) Other prescribers in Torrance, CA | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 25 payments worth $3,496 in total to this clinician.
| Genentech USA, Inc. | $2,403 |
|---|---|
| Ocular Therapeutix, Inc. | $519 |
| Alcon Vision LLC | $171 |
| Astellas Pharma US Inc | $112 |
| AbbVie Inc. | $71.26 |
| Harrow Eye, LLC | $55.12 |
| Regeneron Healthcare Solutions, Inc. | $39.38 |
| Apellis Pharmaceuticals, Inc. | $31.67 |
| Consulting Fee | $2,370 |
|---|---|
| Food and Beverage | $676 |
| Long term medical supply or device loan | $450 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Apr 25, 2025 | Consulting Fee Susvimo · Immunology and Ophthalmology | $2,370 |
| Ocular Therapeutix, Inc. Jan 21, 2025 | Long term medical supply or device loan DEXTENZA · Corticosteroid intracanalicular insert · in-kind | $240 |
| Ocular Therapeutix, Inc. Jan 21, 2025 | Long term medical supply or device loan DEXTENZA · Corticosteroid intracanalicular insert · in-kind | $210 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $750,691 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.